Trials / Completed
CompletedNCT01735201
AGN-199201 for the Treatment of Erythema With Rosacea
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 357 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-199201 Dose A | AGN-199201 Dose A applied once or twice daily to the face for 28 days. |
| DRUG | AGN-199201 Dose B | AGN-199201 Dose B applied once or twice daily to the face for 28 days. |
| DRUG | AGN-199201 Dose C | AGN-199201 Dose C applied once or twice daily to the face for 28 days. |
| DRUG | AGN-199201 Vehicle | AGN-199201 Vehicle applied once or twice daily to the face for 28 days. |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-05-01
- Completion
- 2013-06-01
- First posted
- 2012-11-28
- Last updated
- 2019-11-18
- Results posted
- 2014-05-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01735201. Inclusion in this directory is not an endorsement.